Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601583 · ClinicalTrials.gov registry record · Phase 1
Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment
A Phase 1 study of Type 2 Diabetes and Mild Cognitive Impairment, sponsored by NYU Langone Health.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05601583 is a Phase 1 study of Type 2 Diabetes and Mild Cognitive Impairment that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 14 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05601583, a Phase 1 study of Type 2 Diabetes and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Eligible older adults with Type 2 Diabetes-Mild Cognitive Impairment (T2D-MCI) will be provided a Continuous Glucose Monitoring (CGM) device and asked to share CGM data with their care partners for daily decision-making for diabetes self-management. After 2 weeks, individual interviews will be conducted in 20 participants (10 dyads). Older adults with T2D-MCI (n=10) and their care partners (n=10) will be interviewed separately to identify key features of the Care Partner-Assisted Intervention through linking continuous glucose monitoring and Mobile Health (CP-CGMH) app.
Conditions Studied
Interventions
- DEVICE Continuous Glucose Monitor (CGM)
Study Locations (1)
New York
- Bellevue Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05601583
The ClinicalTrials.gov registry entry for NCT05601583 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitor (CGM) is the first listed.
NCT05601583 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05601583 about?
NCT05601583 is a clinical study titled "Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment". Eligible older adults with Type 2 Diabetes-Mild Cognitive Impairment (T2D-MCI) will be provided a Continuous Glucose Monitoring (CGM) device and asked to share CGM data with their care partners for daily decision-making for diabetes self-management. After 2 weeks, individual interviews will be condu...
What is the current status of trial NCT05601583?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-04-19. Estimated completion is 2027-08-31.
What conditions does trial NCT05601583 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Mild Cognitive Impairment.
What interventions are being tested in trial NCT05601583?
The interventions under investigation include: Continuous Glucose Monitor (CGM) (DEVICE).
Who is sponsoring clinical trial NCT05601583?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05601583 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Pioglitazone, and Ketone Production in T2D
RECRUITING · Phase 1
-
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.